Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)

Yao Zhu,1,2 Dingwei Ye1,2 On behalf of the Expert Group1Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China; 2Department of Oncology, Shanghai Medical School, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence: Dingwei YeDepartment of Oncology, Shanghai Medical School, Fudan University, No. 270 Dongan Road, Shanghai 200032, People’s Republic of ChinaTel +86 13 701663571Email dwyeli@163.comAbstract: Currently, the basic treatment of advanced prostate cancer is still endocrine therapy, but almost all patients eventually progress to castration-resistant prostate cancer (CRPC). In 2016, the Chinese Expert Consensus on the Diagnosis and Treatment of CRPC which aimed to help Chinese clinicians formulate treatment plans for CRPC was published. In this 2019 update, the 2016 version was updated with the aim of providing a more appropriate reference for clinical practice, standardizing CRPC patient management, and facilitating decision-making. The consensus is evidence-based and reviews the optimal therapeutic recommendations for CRPC management in China by taking into consideration the clinical characteristics of Chinese patients; drug availability, efficacy and safety; and recent advancements and developments in the international medical arena.Keywords: prostate cancer, castration-resistant, metastases, treatment, expert consensus